Determination of the glucocorticoid fluticasone propionate in plasma by automated solid-phase extraction and liquid chromatography-tandem mass spectrometry.
A sensitive, robust and high throughput mass spectrometry based method is described for the determination of the glucocorticoid fluticasone propionate in plasma. The method employs solid-phase extraction in 96 well microtitre plate format which has been automated by means of a custom built Zymark robotic system. The extracts are analysed by liquid chromatography-tandem mass spectrometry using thermally and pneumatically assisted electrospray ionisation and selected reaction monitoring. The method is both accurate and precise with both intra- and inter-assay precision (C.V.) of less than <6%. The method provides a lower limit of quantification of 20 pg/ml from 0.5 ml of human plasma, sufficient to monitor systemic concentrations of inhaled fluticasone propionate at therapeutic doses.
Callejas
S L
SL
Department of International Bioanalysis, GlaxoWellcome Research and Development, Ware, Herts, UK.
Biddlecombe
R A
RA
Jones
A E
AE
Joyce
K B
KB
Pereira
A I
AI
Pleasance
S
S
D000730:Androstadienes / Q000097:blood*; D018927:Anti-Asthmatic Agents / Q000097:blood*; D000893:Anti-Inflammatory Agents / Q000097:blood*; D002853:Chromatography, Liquid / Q000379:methods*; D000068298:Fluticasone; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D000068298:Fluticasone